190 related articles for article (PubMed ID: 12424542)
1. Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation.
Nakai K; Kanda Y; Mineishi S; Hori A; Chizuka A; Niiya H; Tanimoto T; Ohnishi M; Kami M; Makimoto A; Tanosaki R; Matsuno Y; Yamazaki N; Tobinai K; Takaue Y
Ann Hematol; 2002 Oct; 81(10):593-6. PubMed ID: 12424542
[TBL] [Abstract][Full Text] [Related]
2. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation.
Messina G; Quartarone E; Console G; Cuzzola M; Iacopino O; Martino M; Irrera G; Morabito F; Iacopino P
Haematologica; 2002 Jul; 87(7):ECR22. PubMed ID: 12091138
[TBL] [Abstract][Full Text] [Related]
3. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
Saito T; Kanda Y; Nakai K; Kim SW; Arima F; Kami M; Tanosaki R; Tobinai K; Wakasugi H; Heike Y; Mineishi S; Takaue Y
Bone Marrow Transplant; 2003 Sep; 32(6):601-8. PubMed ID: 12953133
[TBL] [Abstract][Full Text] [Related]
4. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
7. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y
Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
12. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Aspergillus ustus in a lung transplant recipient: emergence of a new opportunistic fungal pathogen.
Vagefi PA; Cosimi AB; Ginns LC; Kotton CN
J Heart Lung Transplant; 2008 Jan; 27(1):131-4. PubMed ID: 18187099
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation.
Ayas M; Al-Jefri A; Al-Mahr M; Rifai S; Moussa E; Karaoui M; Roberts G; El-Solh H
Bone Marrow Transplant; 2004 Jan; 33(1):15-7. PubMed ID: 14578932
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous aspergillosis as a first manifestation of systemic infection in allogeneic haematopoietic stem cell transplantation.
Hashmi KU; Ahmed P; Satti TM; Raza S; Chaudhry QU; Ikram A; Kamal MK; Akhtar FM
J Pak Med Assoc; 2007 Jun; 57(6):324-6. PubMed ID: 17629239
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
18. [Primary cutaneous aspergillosis in a leukemic child].
Torrelo A; Hernández-Martín A; Scaglione C; Madero L; Colmenero I; Zambrano A
Actas Dermosifiliogr; 2007 May; 98(4):276-8. PubMed ID: 17506961
[TBL] [Abstract][Full Text] [Related]
19. [Acute myeloid leukemia with Aspergillus tracheobronchitis after allogeneic peripheral blood stem cell transplant].
Doki N; Saito Y; Hatsumi N; Irisawa H; Sakura T; Miyawaki S
Rinsho Ketsueki; 2004 Sep; 45(9):1017-22. PubMed ID: 15510828
[TBL] [Abstract][Full Text] [Related]
20. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
